|52 Week Range||36.91-57.82|
|1y Target Est||-|
|DCF Unlevered||SNY DCF ->|
|DCF Levered||SNY LDCF ->|
|Debt / Equity||69.83%||Buy|
Upgrades & Downgrades
Latest SNY news
US FDA panel backs Sanofi-AstraZeneca's preventive RSV therapy
8 June 2023
The U.S. Food and Drug Administration advisers on Thursday backed the use of Sanofi and partner AstraZeneca's experimental antibody to prevent respiratory syncytial virus (RSV) infections in infants.
FDA advisers vote in favor of AstraZeneca, Sanofi antibody for infant RSV protection
8 June 2023
Advisers to the U.S. Food and Drug Administration voted unanimously Thursday to recommend a monoclonal antibody developed by Sanofi SNY, +1.30% and AstraZeneca AZN, +1.28% to protect infants from resp...
International Wide-Moat Stocks On Sale - The June 2023 Heat Map
7 June 2023
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued. We share the heat map of the most investable candida...
GSK's RSV Vaccine Arexvy Gets EU Approval for Older Adults
7 June 2023
The approval of GSK's RSV vaccine for older adults is based on positive data from the pivotal AReSVi-006 phase III study.
US FDA staff flag no new safety issues for Sanofi-AstraZeneca's preventive RSV therapy
6 June 2023
The U.S. Food and Drug Administration's staff reviewers on Tuesday raised no new concerns on Sanofi and partner AstraZeneca's experimental therapy to prevent respiratory syncytial virus (RSV) infectio...
Are You Looking for a High-Growth Dividend Stock?
5 June 2023
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes?
Sanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal
31 May 2023
Sanofi's (SNY) phase II study on its novel investigational anti-CD40L antibody, frexalimab, meets the primary endpoint.
Sanofi announces positive data for frexalimab product to treat multiple sclerosis
31 May 2023
French healthcare company Sanofi announced on Wednesday positive data for its frexalimab product aimed at treating multiple sclerosis, and that the firm plans to initiate pivotal trials in multiple sc...
2 Bear Market Defying Stocks to Buy in May
22 May 2023
Sanofi's wide lineup of medicines across several therapeutic areas makes it attractive. Axsome Therapeutics is rising in prominence thanks to an exciting pipeline.
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >